CVTX 
By The event will be webcast live and available for replay on the company's Web site, www.cvt.com.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in
CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.
CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.
Except for the historical information contained herein, the matters set
forth in this press release are forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially, including
operating losses and fluctuations in operating results; capital requirements;
regulatory review and approval of our products; special protocol assessment
agreement; the conduct and timing of clinical trials; commercialization of
products; market acceptance of products; product labeling; concentrated
customer base; reliance on strategic partnerships and collaborations;
uncertainties in drug development; uncertainties regarding intellectual
property; and other risks detailed from time to time in CV Therapeutics' SEC
reports, including its Quarterly Report on Form 10-Q for the quarter ended
SOURCE CV Therapeutics, Inc.
